Condition: Severe Aplastic Anemia · Relapse · Refractory · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This trial is exploratory research aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD13-02, a universal CD7 CAR T therapy, in subjects with relapsed/refractory severe aplastic anemia (SAA)
This description comes directly from the study's public registry record.
Jun Shi, PhD · 13752253515 · shijun@ihcams.ac.cn
Lele Zhang, PhD · 15811139278 · zhanglele@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Regenerative Medicine Clinic Center | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06622694